Who are Inhibitors, ACE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vasotec, Ramipril + Irbesartan, RAS Inhibitors, ACEI / ARB+finerenone, Renin-angiotensin system blockers, Ramipril (ACE-inhibitor).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inhibitors-ace.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Inhibitors, ACE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhibitors, ACE (Inhibitors, ACE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

phase 3 ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Inhibitors, ACE (Inhibitors, ACE) — National Heart, Lung, and Blood Institute (NHLBI). ACE inhibitors block the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II and thereby reducing vasoconstriction and aldosterone release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inhibitors, ACE TARGET	Inhibitors, ACE	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
Ramipril + Irbesartan	Ramipril + Irbesartan	Bristol-Myers Squibb	marketed	ACE inhibitor + Angiotensin II receptor blocker combination	ACE enzyme and AT1 angiotensin II receptor
RAS Inhibitors	RAS Inhibitors	Shenzhen Second People's Hospital	marketed	ACE inhibitor or Angiotensin II receptor blocker (ARB)	ACE enzyme or Angiotensin II Type 1 receptor (AT1R)
ACEI / ARB+finerenone	ACEI / ARB+finerenone	Capital Institute of Pediatrics, China	marketed	ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination	Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor
Renin-angiotensin system blockers	Renin-angiotensin system blockers	Hospital Authority, Hong Kong	marketed	ACE inhibitors / Angiotensin II receptor blockers (ARBs)	ACE enzyme or AT1 receptor
Ramipril (ACE-inhibitor)	Ramipril (ACE-inhibitor)	National Heart Institute, Egypt	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
Bioprojet · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
Children's Hospital of Fudan University · 1 drug in this class
Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Ethicare GmbH · 1 drug in this class
Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inhibitors, ACE — Competitive Intelligence Brief. https://druglandscape.com/ci/inhibitors-ace. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing